Charles Schwab Investment Management Inc. Increases Holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Charles Schwab Investment Management Inc. grew its stake in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 3.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 567,063 shares of the company’s stock after buying an additional 21,255 shares during the period. Charles Schwab Investment Management Inc. owned 0.58% of Poseida Therapeutics worth $1,622,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Marshall Wace LLP bought a new stake in shares of Poseida Therapeutics in the second quarter worth about $31,000. Principal Financial Group Inc. purchased a new stake in shares of Poseida Therapeutics during the 2nd quarter worth $35,000. Rothschild Investment LLC purchased a new stake in Poseida Therapeutics during the second quarter valued at approximately $35,000. Intech Investment Management LLC acquired a new stake in Poseida Therapeutics in the third quarter worth about $46,000. Finally, Mackenzie Financial Corp acquired a new stake in shares of Poseida Therapeutics during the second quarter worth $51,000. 46.87% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on PSTX. Cantor Fitzgerald downgraded Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 26th. Piper Sandler downgraded Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 target price on the stock. in a research note on Monday, December 2nd. BTIG Research restated a “neutral” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 price target (down from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $9.50.

Insider Buying and Selling at Poseida Therapeutics

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.46, for a total value of $283,800.00. Following the sale, the chairman now owns 651,291 shares of the company’s stock, valued at $6,161,212.86. The trade was a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.90% of the stock is currently owned by company insiders.

Poseida Therapeutics Stock Performance

Shares of PSTX opened at $9.51 on Tuesday. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. The firm has a 50-day moving average price of $4.71 and a 200 day moving average price of $3.59. Poseida Therapeutics, Inc. has a 12-month low of $1.87 and a 12-month high of $9.58. The firm has a market capitalization of $929.79 million, a P/E ratio of -15.10 and a beta of 1.64.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.